Evaluating safety and efficacy with our psilocybin trials
As part of our initiative to move psilocybin toward legalization, we are working with Health Canada to conduct multiple clinical trials evaluating its safety and efficacy. Following the completion of our Phase I clinical trial in 2022, we are now looking to conduct our Phase II clinical trial for efficacy that runs along with ATMA’s Advanced Psychedelic-assisted Therapy (PaT) Certification Program.
As our Clinical Trials are available only to registered frontline healthcare workers who have completed an approved psilocybin-assisted therapy training program, we invite you to look at our available Training Programs.
A Phase II Study with the intent to assess the efficacy of psilocybin when administered to frontline healthcare workers with COVID-19-related mental health concerns.
A Phase I Study with the intent to assess the safety of psilocybin when administered to healthy participants. This clinical trial for psilocybin-assisted therapy will evaluate the safety and tolerability of psilocybin in the healthcare practitioners.
End-of-life anxiety in palliative care patients is extremely prevalent, and conventional methods are not always sufficient in treating such anxiety. Psilocybin-assisted therapy not only holds the promise of high levels of efficacy, but also allows for patients to discover personal insights in a shorter period of time than conventional methods, which is crucial for palliative care patients whose time is limited.
It is important for this population of patients to have access to this medicine, and the evaluation of safety and efficacy of psilocybin in this population will move it closer to legalization. This is a psychedelic clinical trial that we plan to undertake in the near future.
Terminal cancer patient Tony White is the first Albertan to have undergone legal psychedelic therapy in Canada since Health Canada started allowing palliative care patients to take magic mushrooms to relieve end-of-life distress last year.